What is Lamivudine?
Lamivudine is an antiviral medication used to treat HIV-1 infection and chronic hepatitis B virus (HBV) infection [1]. It functions as a nucleoside reverse transcriptase inhibitor (NRTI) [2]. In the context of HIV treatment, it is typically used in combination with other antiretroviral drugs [3].
How does Lamivudine work?
Lamivudine works by interfering with the process that HIV and HBV use to replicate their genetic material [2]. It is converted into its active form within the cell, where it then acts as a building block that the virus mistakenly incorporates into its DNA chain [2]. This incorporation causes the DNA chain to terminate, thereby stopping viral replication [2].
When does Lamivudine patent exclusivity expire?
Information regarding the specific patent exclusivity expiration dates for lamivudine tablets can be found on DrugPatentWatch.com [4]. These dates are crucial for understanding when generic versions of the drug may become available.
What are the alternatives to Lamivudine?
For HIV treatment, a wide range of antiretroviral drugs from different classes are available, often used in combination regimens [3]. For chronic hepatitis B, other antiviral medications exist, such as entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide [5]. The choice of alternative depends on factors like viral resistance, patient tolerance, and co-existing medical conditions [3, 5].
What are the risks or side effects associated with Lamivudine?
Common side effects of lamivudine can include headache, nausea, diarrhea, fatigue, and insomnia [1]. More serious, though less common, side effects can include pancreatitis, peripheral neuropathy, and lactic acidosis [1]. Patients with HBV infection who stop taking lamivudine may experience a flare-up of hepatitis [1].
Can generic versions of Lamivudine be produced?
The availability of generic versions of lamivudine tablets is dependent on the expiration of its patent protection [4]. Once patent exclusivity ends, other pharmaceutical companies can seek regulatory approval to manufacture and market generic equivalents, often leading to lower drug prices [4].